Suven Life Sciences Ltd has been granted product patent in Israel, Japan and South Africa for its new chemical entities (NCEs) used in the treatment of disorders associated with neurodegenerative (or central nervous system) diseases.
The granted claims of the patents include the class of selective 5-HT compounds discovered by Suven and are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer’s disease, Attention deficient hyperactivity disorder (ADHD), Huntington’s disease, Parkinson and
Schizophrenia.
With these new patents, Suven has been granted six, 17 and 20 product patents from Israel, Japan and South Africa respectively. These granted patents are exclusive intellectual property of Suven and are achieved through the internal discovery research efforts.
The granted claims of the patents include the class of selective 5-HT compounds discovered by Suven and are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer’s disease, Attention deficient hyperactivity disorder (ADHD), Huntington’s disease, Parkinson and
Schizophrenia.
With these new patents, Suven has been granted six, 17 and 20 product patents from Israel, Japan and South Africa respectively. These granted patents are exclusive intellectual property of Suven and are achieved through the internal discovery research efforts.